Status:
COMPLETED
A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
Lead Sponsor:
GlaxoSmithKline
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study represents the first administration of GSK376501 in humans and the goal is to evaluate its initial safety and tolerability. The way the human body processes GSK376501 will also be determine...
Detailed Description
A Single-Blind, Randomized, Placebo Controlled, Ascending Single and Repeat Dose Study with Once Daily Dosing to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK376501 ...
Eligibility Criteria
Inclusion
- Inclusion:
- Healthy
- Non-smoking
- Overweight or obese subjects with a BMI between 27 and 35.
- Exclusion:
- Women who are pregnant, lactating, or are of child-bearing potential
Exclusion
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00404963
Start Date
October 1 2006
End Date
May 1 2007
Last Update
January 19 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Evansville, Indiana, United States, 47714